Evidence map›Paper›PMID 40476597›Full record

ArticleClinical science (London, England : 1979)2025

Primary bile acid shapes peripheral immunity in inflammatory bowel disease-associated primary sclerosing cholangitis.

André A Santos, David Pires, Vanda Marques, Nicole Alesina, Elisa Herraez, Pavel Roudnický, Pedro M Rodrigues, Ana Godinho-Santos, Ana Catarina Bravo, Catarina Gouveia and 11 more

Abstract read
In one paragraph

Article in Clinical science (London, England : 1979), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

André A SantosResearch Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Lisboa, Portugal.ORCID 0000-0002-3248-1051
David PiresCIIS - Centro de Investigação Interdisciplinar em Saúde, Faculdade de Medicina, Universidade Católica Portuguesa, Lisboa, Portugal.
Vanda MarquesResearch Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Lisboa, Portugal.
Nicole AlesinaResearch Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Lisboa, Portugal.
Elisa HerraezExperimental Hepatology and Drug Targeting (HEVEPHARM), Institute of Biomedical Research of Salamanca (IBSAL), University of Salamanca, Salamanca, Spain.
Pavel RoudnickýMendel Centre of Plant Genomics and Proteomics, Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
Pedro M RodriguesCenter for the Study of Liver and Gastrointestinal Diseases (CIBERehd), Carlos III National Institute of Health, Madrid, Spain.
Ana Godinho-SantosResearch Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Lisboa, Portugal.
Ana Catarina BravoDivision of Gastroenterology, Hospital Beatriz Ângelo, Loures, Portugal.
Catarina GouveiaDivision of Gastroenterology, Hospital Beatriz Ângelo, Loures, Portugal.
Susana SaraivaDivision of Gastroenterology, Hospital Beatriz Ângelo, Loures, Portugal.
Luís CorreiaDivision of Gastroenterology, ULS Santa Maria, Lisboa, Portugal.
Ricardo CrespoDivision of Gastroenterology, Hospital Lusíadas, Lisboa, Portugal.
João Pereira da SilvaDivision of Gastroenterology, Hospital Lusíadas, Lisboa, Portugal.
Marília CravoDivision of Gastroenterology, Hospital da Luz, Lisboa, Portugal.
David PotesilMendel Centre of Plant Genomics and Proteomics, Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
Zbyněk ZdráhalMendel Centre of Plant Genomics and Proteomics, Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
Jesus Maria BanalesCenter for the Study of Liver and Gastrointestinal Diseases (CIBERehd), Carlos III National Institute of Health, Madrid, Spain.
Jose J G MarinExperimental Hepatology and Drug Targeting (HEVEPHARM), Institute of Biomedical Research of Salamanca (IBSAL), University of Salamanca, Salamanca, Spain.
Joana TorresCenter for the Study of Liver and Gastrointestinal Diseases (CIBERehd), Carlos III National Institute of Health, Madrid, Spain.
Cecília Maria Pereira RodriguesResearch Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Lisboa, Portugal.

Funding

AECC Scientific Foundation (2023/2027). Ministerio de Ciencia e Innovación. PID2022-140210OB-I00CEITEC Proteomic Core Facility, a part of Czech Infrastructure for Integrative Structural Biology (CIISB), Instruct-CZ Centre of Instruct-ERIC EU consortium funded by Instruct-ERIC PID 23709European Association for the Study of the Liver Daniel Alagille Award 2019Fondo de Investigaciones Sanitarias, Instituto de Salud Carlos III, Spain, co-funded by the European Regional Development Fund/European Social Fund, "Investing in your future" PI22/00526Fundação para a Ciência e a Tecnologia CEECIND/04663/2017Grupo de Estudos da Doença Intestinal Inflamatória GEDII Project Award 2019Instituto de Salud Carlos III PI21/00922 - PI18/01075Junta de Castilla Control Leon SA113P23Miguel Servet plus Fondo Europeo de Desarrollo Regional" (FEDER) CPII19/00008Ministry of Education, Youth and Sports CR LM2023042 and e-INFRA CZ (ID:90254)
6 · The paper itself

Abstract

Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease often associated with underlying inflammatory bowel disease (IBD). This study investigates how PSC predisposes individuals to altered inflammatory immune responses compared with IBD alone. A case-control study was conducted with a cohort of 75 patients, including 16 with PSC (14 with concomitant IBD), 39 with IBD alone, and 20 controls. Serum bile acid profile, proteomic analysis, and immune-related gene expression in the colon tissue were examined. Colonic tissue from PSC patients exhibited up-regulation of immune regulation and inflammatory signaling mRNA markers, including LGR5, IL-8, CCL2, COX2, TWIST1, and SNAIL. Additionally, PSC patients displayed a distinct proinflammatory serum proteomic signature and moderate elevation of some bile acids, such as glycochenodeoxycholic acid (GCDCA). Co-incubation of human-derived monocytes with GCDCA partially replicated the inflammatory profile observed in PSC. These findings suggest that circulating bile acids modulate the peripheral immune system proinflammatory response, contributing to the unique PSC phenotype.

Indexed as

Bile Acids and SaltsCholangitis, SclerosingInflammatory Bowel DiseasesAdultCase-Control StudiesColonFemaleHumansMaleMiddle AgedMonocytesProteomicsBile Acids and Saltsbile acidsGCDCAIBDimmune responsePSC

Identifiers

PMID40476597
PMCPMC12312387

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.